Theranostic in Oncology: Precision Targeting with Radioligand Therapy View PDF

Theranostics in oncology represents a transformative approach that integrates diagnostic imaging and targeted therapy, offering the promise of precision medicine tailored to individual tumor biology [1-5]. Recent advancements have focused on developing radioligand therapies that exploit specific molecular targets within tumors, enabling both visualization and eradication of malignant cells [6, 7]. The evolution of this field is underpinned by a deeper understanding of tumor heterogeneity, molecular profiling, and innovative delivery systems, as evidenced by the comprehensive reviews and studies available in recent literature.

One of the foundational concepts in theranostics is the identification of specific molecular targets expressed predominantly or exclusively on tumor cells. For instance, neuroendocrine neoplasms and prostate cancer have been at the forefront of radioligand theranostics, with high levels of somatostatin receptor and prostate-specific membrane antigen (PSMA) expression, respectively. Ferdinandus et al. [8] highlights the clinical success of imaging and therapy targeting these receptors, demonstrating how high receptor expression facilitates effective patient selection and response assessment through radioligand scintigraphy and positron emission tomography (PET). These approaches exemplify the core principle of theranostics: using molecular imaging to guide targeted radionuclide therapy, thereby improving outcomes.

The development of novel radioligands targeting other tumorassociated proteins further expands the theragnostic landscape. Lindner et al. [9] discussed fibroblast activation protein as a promising target, emphasizing that fibroblast activation protein targeted radiopharmaceuticals do not require extensive patient preparation, unlike traditional tracers such as Fluorine-18 fluorodeoxyglucose [18F] FDG. This attribute simplifies clinical workflows and enhances the feasibility of theranostic applications across various tumor types. The versatility of radioligands is also demonstrated by the development of agents like [I]GD1, a radiolabeled poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor designed for Auger electron therapy, as presented by Destro et al. [10]. This agent exemplifies the integration of diagnostic imaging with therapeutic potential, leveraging the radiolabeling of molecules involved in deoxyribonucleic acid (DNA) repair pathways to achieve targeted cytotoxicity.

The clinical translation of theranostics has been accelerated by landmark approvals such as Lutathera and Pluvicto, which have demonstrated the efficacy of radioligand therapy in neuroendocrine tumors and prostate cancer, respectively. Tran et al. [11] reviews the evolving landscape, emphasizing how these successes have catalyzed research into novel radionuclides, targeting strategies, and combination therapies. The integration of radiotheranostics with other treatment modalities, including immunotherapy and molecular targeted agents, is increasingly recognized as a promising avenue to overcome resistance and tumor heterogeneity. Bristow et al. [12] advocate for combining precision radiotherapy with molecular targeting and immunomodulatory agents, underscoring the importance of a multimodal approach in personalized cancer treatment. The role of molecular profiling in guiding theranostic strategies is well documented. Miklja et al. [13] demonstrate how comprehensive genomic and transcriptomic analyses facilitate the identification of actionable targets in pediatric gliomas, enabling tailored therapeutic interventions. Similarly, Sicklick et al. [14] propose that personalized combination therapies, informed by molecular profiling, can address the complexity and heterogeneity of refractory cancers, thereby improving clinical outcomes. These studies underscore the importance of integrating molecular diagnostics with theranostic approaches to realize the full potential of precision oncology.

Nanotechnology has emerged as a complementary platform to enhance theranostic efficacy. Al-Thani et al. [15] reviews how nanoparticles, such as gold, iron oxide, and liposomes, can be engineered to serve as both imaging agents and drug delivery vehicles. These nanoplatforms offer advantages including improved targeting, controlled release, and reduced systemic toxicity, making them highly suitable for personalized theranostic applications. The combination of nanotechnology with radioligand therapy holds promise for overcoming current limitations related to tumor penetration and off-target effects. Emerging radionuclides and innovative targeting strategies continue to shape the future of theranostics. Watabe et al. [16] discussed the development of novel radionuclides and tumor targets, such as trophoblast cell-surface antigen 2 (TROP-2) and nectin-4, which are under clinical investigation. The ability to switch radionuclides—using diagnostic isotopes for imaging and therapeutic isotopes for treatment—embodies the essence of theranostics, allowing for real-time monitoring and adaptive treatment planning. Turner [17] emphasizes that the timing of theranostic interventions is critical, advocating for personalized scheduling based on tumor response and progression.

In summary, the current state of theranostics in oncology is characterized by significant progress in target identification, radioligand development, and clinical implementation. The integration of molecular diagnostics, advanced imaging, and targeted radionuclide therapy exemplifies the shift toward precision medicine, aiming to improve efficacy while minimizing toxicity. As research continues to evolve, the combination of nanotechnology, novel radionuclides, and comprehensive molecular profiling is poised to further refine theranostic strategies, ultimately transforming cancer management into a more personalized and effective discipline.